PMC:7784830 / 16111-16390 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"254","span":{"begin":120,"end":128},"obj":"Disease"}],"attributes":[{"id":"A254","pred":"tao:has_database_id","subj":"254","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Chinese National Health Commission announced, dated 14 April 2020, three patented Chinese herbal drugs for treatment of COVID-19 which include namely: ‘Lianhuaqingwen capsules and Jinhuaqinggan granules for mild conditions, and Xuebijing (injectable) for severe conditions’ [80]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T124","span":{"begin":0,"end":279},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Chinese National Health Commission announced, dated 14 April 2020, three patented Chinese herbal drugs for treatment of COVID-19 which include namely: ‘Lianhuaqingwen capsules and Jinhuaqinggan granules for mild conditions, and Xuebijing (injectable) for severe conditions’ [80]."}